Contact   |    Careers   |    Employees   |    Physicians

Gynecologic Oncology


 
 
 

Departments

 
 
 

Gynecologic Oncology & Surgery - Clinical Trials for Gynecologic Malignancies

Clinical Trials for Gynecologic Malignancies Open for Patient Enrollment

I. Uterus 

A.   Endometrium:
1. GOG 249: A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy  Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High risk, Early Endometrial Carcinoma
 
a. Who is eligible?
-patients who have undergone surgery- hysterectomy (removal of uterus) and 
bilateral salpingo-oophorectomy (removal of tubes and ovaries) and whose final pathology demonstrates intermediate-high risk factors such as:
*grade 2 or 3 tumor,
*lymphovascular space invasion (LVSI), 
*outer half of myometrial (uterine muscle) invasion
*high risk cell types: clear cell and serous cell type
*involvement with cancer of the cervix
 
b. Point of contact: Dr. Mildred R. Chernofsky- 202-243-5295 or RN Leslie Greenberg 202-243-2320
 
c. Additional information:  http://clinicaltrials.gov/
 
2. GOG 258: A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma
 
a. Who is eligible?
-Patients who have undergone surgery- hysterectomy (removal of uterus) and 
bilateral salpingo-oophorectomy (removal of tubes and ovaries) and whose final pathology demonstrates surgical stage III or IVA (with less than 2 cm residual disease)
 
b. Point of contact: Dr. Mildred R. Chernofsky- 202-243-5295 or RN Leslie Greenberg 202-243-2320
 
c. Additional information:  http://clinicaltrials.gov/  
 
 

II. Ovary (or fallopian tube or primary peritoneum)

A. Epithelial:
1. GOG 262: A Randomized Phase III Trial of Every-3-Weeks Paclitaxel Versus Dose Dense Weekly Paclitaxel in Combination With Carboplatin With or Without Concurrent and Consolidation Bevacizumab in the Treatment of Primary Stage II, III or IV Epithelial Ovarian, Peritoneal or Fallopian Tube Cancer 
 
a. Who is eligible?
-Patients who have undergone surgery whose final pathology demonstrates a diagnosis of epithelial ovarian cancer, fallopian tube cancer or primary peritoneal carcinoma with a surgical stage of III or IV 
 
b. Point of contact: Dr. Mildred R. Chernofsky- 202-243-5295 or RN Leslie Greenberg 202-243-2320
 
 
2. GOG 212: A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103 versus No Treatment Until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane
 
a. Who is eligible?
-Patients diagnosed with primary peritoneal cancer or Stage III or Stage IV ovarian or fallopian tube cancer, who have: no symptoms suggestive of persistent cancer, normal physical exam, normal CT scan of the abdomen and pelvis and normal CA 125 after receiving 5-8 cycles of platinum-taxane therapy  
 
b. Point of contact: Dr. Mildred R. Chernofsky- 202-243-5295 or RN Leslie Greenberg 202-243-2320
 
c. Additional information:  http://clinicaltrials.gov/

III. Cervix

1.   GOG 263: Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
 
a.   Who is eligible?   
 
-Patients who have undergone surgery whose final pathology demonstrates a diagnosis of cervical cancer with a surgical stage of I or IIA 
 
b.   Point of contact: Dr. Mildred R. Chernofsky- 202-243-5295 or RN Leslie Greenberg 202-243-2320 
 
c.   Additional information:  http://clinicaltrials.gov/ct2/show/NCT01101451 
 
 
 
© Copyright 2013 Sibley Memorial Hospital